



**Association for Molecular Pathology**  
*Promoting Clinical Practice, Translational Research, and Education in Molecular Pathology*  
9650 Rockville Pike, Bethesda, Maryland 20814  
Tel: 301-634-7939 ▪ Fax: 301-634-7990 ▪ Email: [amp@amp.org](mailto:amp@amp.org) ▪ [www.amp.org](http://www.amp.org)

## **FOR IMMEDIATE RELEASE**

### **AMP Releases Proposal Addressing CPT Coding for GSAs**

**Bethesda, MD, March 20, 2013:** The Association for Molecular Pathology (AMP) has submitted to the American Medical Association's CPT Editorial Panel its proposal addressing CPT coding for genomic sequencing assays (GSAs). The proposal was developed by the AMP Economic Affairs Committee, which is co-chaired by Aaron Bossler, MD, PhD, and Jan Nowak, MD, PhD. The scope of the committee includes developing and advocating for sound economic policies that promote the provision of high quality molecular pathology services. "The report documents the challenges, related technology, and proposed coding scheme for GSAs," said Nowak. "We are interested in the feedback of AMP members and others with a vested interest in the coding framework. We hope to generate further discussion."

The term "GSAs" stands for "genomic sequencing assays." The EAC adopted this term "as a more general term with breadth enough to allow for future technologies and applications to be included under this heading" said Bossler.

The ability to so closely examine the human genome has and will continue to result in the need for countless new codes. The report includes two proposed schemes for coding GSAs; 1) the Technology-Agnostic, Single Code Strategy, and 2) the Code Mate Strategy. Option 1 relies on a single, methodology-agnostic code that includes both technical and interpretive work whereas Option 2 introduces separate codes for technical vs. interpretive processes. To view the full proposal, visit [www.amp.org/CPTforGSAs](http://www.amp.org/CPTforGSAs).

With this new proposal for genomic sequencing assays, AMP follows on its 2011 white paper for CPT Coding molecular pathology tests. "We understand that laboratories throughout the U.S. rely on AMP for molecular pathology expertise," said Jennifer Hunt, MD, AMP President. "We are happy to provide the framework and encourage all stakeholders to provide feedback via email at [NGScomments@amp.org](mailto:NGScomments@amp.org)."

#### **ABOUT AMP:**

The Association for Molecular Pathology (AMP) is an international medical professional association dedicated to the advancement, practice, and science of clinical molecular laboratory medicine and translational research based on the applications of molecular biology, genetics, and genomics. For more information, please visit [www.amp.org](http://www.amp.org).

#### **CONTACT:**

Mary Steele Williams  
[mwilliams@amp.org](mailto:mwilliams@amp.org)  
(301) 634-7921

###